LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

33.98 -1.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

33.92

Max

34.48

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-3.9M 46M
Pardavimai	-17M 185M
P/E Sektoriaus vid.	13.706 54.533
Pelnas, tenkantis vienai akcijai	0.779
Pelno marža	24.663
Darbuotojai	268
EBITDA	-10M 56M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+44.78% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	322M 2.1B
Ankstesnė atidarymo kaina	35.43
Ankstesnė uždarymo kaina	33.98

Naujienos nuotaikos

By Acuity

31%

69%

103 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-21 23:25; UTC

Karštos akcijos

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

2025-05-21 21:57; UTC

Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

2025-05-21 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Operations in Uruguay

2025-05-21 21:01; UTC

Pagrindinės rinkos jėgos

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

2025-05-21 23:49; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

2025-05-21 23:37; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2025-05-21 23:33; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

2025-05-21 23:32; UTC

Įsigijimai, susijungimai, perėmimai

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

2025-05-21 23:32; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

2025-05-21 23:31; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

2025-05-21 23:30; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

2025-05-21 23:29; UTC

Įsigijimai, susijungimai, perėmimai

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

2025-05-21 23:28; UTC

Uždarbis

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

2025-05-21 23:27; UTC

Uždarbis

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

2025-05-21 23:26; UTC

Uždarbis

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

2025-05-21 23:23; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

2025-05-21 23:22; UTC

Svarbiausios naujienos

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

2025-05-21 23:22; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

2025-05-21 23:20; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

2025-05-21 23:18; UTC

Įsigijimai, susijungimai, perėmimai

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

2025-05-21 23:04; UTC

Svarbiausios naujienos

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

2025-05-21 21:46; UTC

Svarbiausios naujienos

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

2025-05-21 21:42; UTC

Svarbiausios naujienos

Įsigijimai, susijungimai, perėmimai

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

2025-05-21 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Millicom to Acquire Telefónica's Ops in Uruguay

2025-05-21 21:07; UTC

Svarbiausios naujienos

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

2025-05-21 21:06; UTC

Įsigijimai, susijungimai, perėmimai

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

44.78% į viršų

12 mėnesių prognozė

Vidutinis 51.57 USD 44.78%

Aukščiausias 70 USD

Žemiausias 31 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

103 / 382 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.